Natera, Inc. ($NTRA) Stock Forecast: Up 5.0% Today

What is Natera, Inc.?

Natera (NTRA) specializes in genetic testing and personalized medicine, particularly in the field of oncology. The company has unveiled a strategic partnership with CytoDyn to progress the development of leronlimab for metastatic colorectal cancer.

Why is Natera, Inc. going up?

NTRA stock is up 5.0% on Jun 4, 2026 18:01

• The collaboration with CytoDyn in the colorectal cancer study has generated positive investor sentiment towards Natera's expertise in oncology, resulting in a bullish uptrend in the stock.
• The inclusion of oncology specialists on Natera's board of directors strengthens the company’s market position and enhances its standing in the realm of personalized medicine.
• Disclosures of a director receiving $425K in RSU equity and the president of clinical diagnostics selling shares have had a marginal effect on stock movement, but the enthusiasm surrounding the strategic collaboration outweighs these transactions.
• Natera's focus on utilizing molecular insights and real-world data to optimize treatment responses in colorectal cancer and other solid tumors underscores its dedication to advancing precision medicine and fostering growth in the oncology sector.

NTRA Price Chart

NTRA Technical Analysis

NTRA News

Natera, CytoDyn Partner in Colorectal Cancer Study

Natera and CytoDyn have formed a strategic collaboration to generate molecular and real-world data for CytoDyn’s metastatic colorectal cancer program. Natera will use its Signatera assay to analyze samples from CytoDyn's CLOVER Phase 2 study, tracking circulating tumor DNA dynamics and molecular response. This partnership aims to provide insights into treatment response and help guide future development strategies for leronlimab, CytoDyn's drug candidate, in colorectal cancer and potentially other solid tumors.

https://www.contractpharma.com/breaking-news/natera-cytodyn-partner-in-colorectal-cancer-study/

Natera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancer

Natera and CytoDyn have announced a strategic collaboration to advance the development of leronlimab for metastatic colorectal cancer (mCRC) using circulating tumor DNA (ctDNA) analysis. Natera's Signatera™ personalized assay will be used to evaluate treatment response in CytoDyn's CLOVER Phase 2 study, while Natera will also provide real-world data analyses to inform future clinical development and patient selection strategies. This partnership aims to leverage molecular insights to optimize the therapeutic potential of leronlimab in oncology.

https://www.stocktitan.net/news/NTRA/natera-and-cyto-dyn-announce-strategic-collaboration-to-advance-ct-avgtqhs523hz.html

Natera (NTRA) director Eric H. Rubin awarded $425K in RSU equity

Natera director Eric H. Rubin was awarded 2,124 shares of Common Stock in the form of Restricted Stock Units (RSUs), valued at $425,000. These RSUs will vest in three equal annual installments starting March 26, 2027, increasing his direct holdings to 2,129 shares. Each RSU represents a contingent right to receive one share of Natera’s Common Stock.

https://www.stocktitan.net/sec-filings/NTRA/form-4-natera-inc-insider-trading-activity-ca28c3b63531.html

Natera (NTRA) clinical diagnostics president sells 3,000 shares under 10b5-1 plan

Solomon Moshkevich, President of Clinical Diagnostics at Natera, Inc. (NTRA), sold 3,000 shares of common stock in pre-scheduled open-market transactions on June 1, 2026. These sales, executed under a Rule 10b5-1 trading plan adopted in November 2024, occurred at weighted-average prices ranging from $217.01 to $220.83 per share. Following these transactions, Moshkevich still directly holds 137,643 shares, indicating the sale represents a minor portion of his overall equity.

https://www.stocktitan.net/sec-filings/NTRA/form-4-natera-inc-insider-trading-activity-73f034dcd082.html

Natera adds two oncology experts to board of directors By Investing.com

Natera Inc. (NASDAQ:NTRA) has expanded its board of directors by appointing oncology experts Thomas Lynch and Eric Rubin. These appointments are aimed at strengthening the company's capabilities in oncology, a sector where Natera has seen significant growth. The company, valued at $30.5 billion, continues to enhance its market presence through strategic partnerships, technological advancements, and a focus on molecular residual disease testing.

https://m.au.investing.com/news/stock-market-news/natera-adds-two-oncology-experts-to-board-of-directors-93CH-4469671?ampMode=1

Trending Today

Kornit Digital Ltd. ($KRNT) Stock Forecast: Down 5.3% Today

Applied Materials Inc. ($AMAT) Stock Forecast: Down 5.7% Today

Lam Research Corporation ($LRCX) Stock Forecast: Down 5.1% Today

Kimberly-Clark Corporation ($KMB) Stock Forecast: Up 5.6% Today

Taiwan Semiconductor Manufacturing Company Ltd. ($TSM) Stock Forecast: Down 5.1% Today

The Cooper Companies Inc. ($COO) Stock Forecast: Up 8.3% Today

Honda Motor Company Ltd. ($HMC) Stock Forecast: Down 5.0% Today

Arista Networks Inc. ($ANET) Stock Forecast: Down 5.0% Today

Peloton Interactive Inc ($PTON) Stock Forecast: Down 5.2% Today

Patterson-UTI Energy Inc. ($PTEN) Stock Forecast: Down 5.4% Today

Natera, Inc. Price History

08.04.2026 - NTRA Stock was down 7.7%

• Despite strong revenue growth driven by successful products like Fetal Focus and Signatera MRD test, Natera faced a bearish movement in its stock, potentially linked to a wider net loss reported in the same quarter, raising concerns about profitability.
• The missed EPS estimate and increased operating expenses leading to a higher net loss are likely factors contributing to the negative market sentiment towards Natera.
• Investors may be concentrating on the company's ability to manage expenses and bottom line performance, somewhat overshadowing the positive revenue growth and raised revenue guidance for the full year.
• The market's response could also be influenced by the stock's recent underperformance compared to the broader market, despite surpassing revenue expectations, suggesting a possible mismatch in investor expectations and market valuation.

15.04.2026 - NTRA Stock was down 5.3%

• Natera's stock experienced a strong bearish movement of 5.9% today.
• The market reacted negatively to Natera's Q1 2026 earnings report despite raising its 2026 revenue and gross margin guidance. This can be attributed to the wider net loss of US$85.09 million due to increased operating expenses for clinical trials, new products, and international expansion.
• Cathie Wood's ARK Invest's strategic shift towards increasing its stake in Natera while selling shares in other biotech companies may have also influenced market sentiment, signaling a shift in focus within the biotech sector.
• Analysts' mixed reactions to Natera's first-quarter results, with revenue beating expectations but statutory losses being larger than forecast, could have added to the overall bearish sentiment surrounding the stock.

20.04.2026 - NTRA Stock was up 5.1%

• The FDA's approval of Natera's Signatera CDx blood test as a companion diagnostic for muscle-invasive bladder cancer has led to a surge in the company's stock performance.
• This approval underscores the importance of MRD testing as a critical tool in clinical decision-making, potentially boosting revenue projections for Natera.
• Despite these positive developments, investors are advised to be wary of Natera's high expenditures, ongoing financial losses, as well as legal and regulatory challenges that could affect its future growth prospects.
• Despite recent declines in the stock price, Natera's robust revenue growth and optimistic analyst outlook suggest that the company may be undervalued, offering investors an opportunity to consider a bullish stance on Natera for the long term.

29.04.2026 - NTRA Stock was up 7.1%

• The bullish movement in Natera's stock could be attributed to the positive market reception of its collaboration with Diakonos Oncology Corp. for a Phase I/II trial in refractory melanoma using the Signatera test. This partnership aims to provide early insights into treatment response dynamics, which is a significant development in the field of personalized medicine.
• The recent sale of shares by the company's executives to cover tax obligations may have initially caused some uncertainty among investors. However, the market seems to have focused more on the promising collaboration and the potential impact on cancer treatment.
• Natera's announcement of an enhanced Panorama non-invasive prenatal test (NIPT) could also have contributed to the positive sentiment, showcasing the company's continued efforts in advancing its genetic testing portfolio and addressing medical needs across different areas.
• Overall, the market's bullish reaction to Natera's strategic collaborations and product enhancements reflects investor confidence in the company's growth prospects and its commitment to driving innovation in genetic testing and personalized medicine.

04.05.2026 - NTRA Stock was up 5.4%

• The bullish movement in Natera's stock today can be attributed to the positive news of the company expanding its board of directors with oncology experts, Thomas Lynch and Eric Rubin. This move is seen as strengthening the company's capabilities in a sector where it has experienced significant growth.
• Additionally, the announcement of Natera expanding its operations in Austin with a new sequencing facility, expected to create 200 new jobs, likely boosted investor confidence in the company's future prospects and growth potential.
• The upgrade of Natera's rating to "Outperform" by Wolfe Research, despite concerns about insider selling, also contributed to the bullish sentiment surrounding the stock. The price target of $260.00 reflects a positive outlook on Natera's performance in the medical diagnostics industry.

04.05.2026 - NTRA Stock was up 5.0%

• The collaboration with CytoDyn in the colorectal cancer study has generated positive investor sentiment towards Natera's expertise in oncology, resulting in a bullish uptrend in the stock.
• The inclusion of oncology specialists on Natera's board of directors strengthens the company’s market position and enhances its standing in the realm of personalized medicine.
• Disclosures of a director receiving $425K in RSU equity and the president of clinical diagnostics selling shares have had a marginal effect on stock movement, but the enthusiasm surrounding the strategic collaboration outweighs these transactions.
• Natera's focus on utilizing molecular insights and real-world data to optimize treatment responses in colorectal cancer and other solid tumors underscores its dedication to advancing precision medicine and fostering growth in the oncology sector.

06.04.2026 - NTRA Stock was up 5.1%

• The bullish movement in Natera's stock today is linked to positive developments such as an "Outperform" rating from William Blair, a patent victory, and promising study results for its Signatera assay.
• The selling of shares by key executives like Sheena Jonathan, John Fesko, and CEO Steven Chapman to cover tax obligations initially raised concerns. However, these pre-arranged transactions, in light of positive news, likely reassured investors about the company's health and future prospects.
• Strategic selling of shares by company insiders under Rule 10b5-1 plans, despite the stock being down year-to-date, may indicate a prudent approach to finance management while maintaining confidence in company performance.
• The combination of positive company developments and strategic insider selling likely fueled the bullish movement in Natera's stock today, demonstrating a blend of financial responsibility and investor confidence in the company's growth trajectory.

30.03.2026 - NTRA Stock was up 5.1%

• The company revealed its first-quarter financial results and held a conference call, potentially boosting investor confidence and fueling the bullish movement.
• Insider selling by the co-founder and CEO, aimed at covering tax obligations, initially raised concerns but a clarified context of these sales being part of a pre-arranged trading plan may have alleviated any negative impact.
• Despite Natera's current lack of profitability, positive court rulings and new analyst coverage could have positively influenced investor sentiment, contributing to the bullish market performance.
• Taken together, positive updates on financial results, structured insider trading activities, and external factors like court decisions and analyst coverage likely played a role in Natera's recent strong bullish trend.

28.04.2026 - NTRA Stock was up 5.1%

• Today's bullish movement in Natera's stock is likely linked to positive updates on its clinical trials and innovations in genetic testing technologies.
• Commencement of patient enrollment for early-stage breast cancer studies and progress in trials for breast cancer and bladder cancer treatments have contributed to increased investor confidence.
• Upgrades to the Panorama prenatal test and FDA approval for Signatera in bladder cancer demonstrate Natera's dedication to innovation and expanding its market reach.
• Despite concerns regarding insider selling and valuation risks, the favorable outcomes in Natera's clinical trials and testing capabilities appear to have had a stronger impact, resulting in an upsurge in the stock price.

02.05.2026 - NTRA Stock was down 5.3%

• The bearish movement in NTRA today could be attributed to the significant insider selling totaling $56.0 million in the last three months, raising concerns among investors about the company's future prospects.
• Despite an optimistic "Outperform" rating and a price target of $260.00, the overvaluation of Natera by 9.2% according to GF Value™ might have contributed to the downward pressure on the stock.
• The rejection of an appeal in the false-advertising dispute with Natera by the U.S. Supreme Court could have added uncertainty and legal risks to Natera's operations, impacting investor confidence in the stock.
• While Natera has announced positive developments such as enhanced prenatal testing and market expansion, the ongoing insider selling and legal disputes might have overshadowed these advancements, leading to the bearish market movement today.

08.04.2026 - NTRA Stock was down 6.0%

• Natera's strong revenue growth and milestone of processing over 1 million tests in a quarter showcased its continued expansion and market demand for its services.
• The wider loss per share than expected could have contributed to the bearish movement in the stock, despite positive revenue performance.
• The sale of shares by the Executive Chairman to cover tax obligations may have also impacted investor sentiment, leading to a decline in the stock price.
• Overall, while Natera's operational performance remains robust, market reaction to the earnings miss and insider selling likely drove the bearish movement in the stock today.

11.04.2026 - NTRA Stock was up 5.1%

• Despite concerns over its high valuation influencing a decline in stock price, Natera's impressive Q1 earnings call, demonstrating revenue growth and increased volume, has boosted investor confidence.
• Analysts have raised the 12-month price target to $260.78, indicating a 19% potential upside, reflecting optimism regarding Natera's future performance.
• The unexpected Q4 profit of US$47.3 million has shifted focus from prior losses to potential growth, although discussions on the stock's valuation persist among investors.
• Analysts' continued Buy rating and optimistic outlook, with target prices spanning from $136 to $285, further bolster the positive trajectory of Natera's stock.